April 19, 2010
Biodesix today announced that results from the VeriStrat biomarker analysis of a Phase III clinical trial will be presented by David Carbone, M.D., Ph.D., Professor of Medicine and Cancer Biology, Vanderbilt University School of Medicine, on Friday, April 30th at the 2nd European Lung Cancer Conference to be held in Geneva. The purpose of the ... Read more
February 5, 2010
Biodesix, Inc. announces that David Brunel, Chief Executive Officer, will present at the 2010 Personalized Medicine Partnerships Conference, Wednesday, February 24th, at 11:00 a.m. eastern time. The conference takes place February 22-24th at the Doubletree Hotel in Philadelphia, PA, and will include presentations by both diagnostic and pharmaceutical companies. Mr. Brunel will provide an overview ... Read more
September 28, 2009
Funding to further the commercialization of VeriStrat®
Biodesix, Inc., a privately held molecular diagnostics company focused on proteomic-based diagnostics discovery and commercialization, announced today that it has completed the initial tranche of its $10 million Series B-1 financing round. The financing was led by existing shareholders and members of the Board of Directors.
“We are excited with ... Read more
May 14, 2009
Data support proteomic test as a predictor of overall survival benefit with EGFRI treatment
Data on VeriStrat, a blood-based, proteomic test currently used for patients with advanced stage non-small-cell lung cancer (NSCLC), will be presented by Christine Chung, MD, Assistant Professor of Medicine at Vanderbilt University on Monday, June 1st at the 45th Annual Meeting of ... Read more
May 5, 2009
Test will help oncologists guide treatment of patients with non-small cell lung cancer
Biodesix, Inc. today announces U.S. commercial availability of VeriStrat, a unique, blood-based, proteomic test for patients with advanced stage non-small cell lung cancer (NSCLC). VeriStrat identifies patients who are likely to have good or poor outcomes following treatment with epidermal growth factor receptor ... Read more
December 5, 2008
Biodesix, Inc, announced today that Paul J. Beresford has joined the Company as Vice President, Business Development and Strategic Marketing, reporting directly to David Brunel, Chief Executive Officer. In this newly created position, Dr. Beresford will help drive all business development activities including the establishment of relationships with pharmaceutical and biotechnology to identify and develop ... Read more
October 31, 2008
Biodesix, Inc. (the “Company”), is pleased to announce receipt of a CLIA registration number 06D1090464 which allows the Company to commercially market VeriStrat®, the serum molecular diagnostic test described in the Journal of the National Cancer Institute 2007 99(11):838-846. The Company is making VeriStrat® available to qualified physicians in locations where the product is compliant with ... Read more
October 1, 2008
Biodesix, Inc, announced today that Douglas E. Swan has joined the Company as Vice President, Commercial Operations, reporting directly to David Brunel, Chief Executive Officer. In this newly created position, Mr. Swan will be responsible for all commercial functions related to the marketing and sales of VeriStrat®. VeriStrat represents the company’s first diagnostic test which ... Read more
